ORBIMED ADVISORS LLC Insider Trading $ORIC Oric Pharmaceuticals, Inc.
Get free email notifications about insider trading for ORBIMED ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ORBIMED ADVISORS LLC. ORBIMED ADVISORS LLC is 10% Owner in CTI BIOPHARMA CORP ($CTIC) and Director in GLAUKOS Corp ($GKOS) and Director in RESPONSE BIOMEDICAL CORP ($RPBIF) and Director in INTERCEPT PHARMACEUTICALS INC ($ICPT) and in ACCELERON PHARMA INC ($XLRN) and Director in ProNAi Therapeutics Inc ($DNAI) and 10% Owner in AVEDRO INC ($AVDR) and 10% Owner in Relypsa Inc ($RLYP) and 10% Owner in Aerpio Pharmaceuticals, Inc. ($ARPO) and Director in Aerpio Pharmaceuticals, Inc. ($ZETAII) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and Director in SELECTA BIOSCIENCES INC ($SELB) and Director in SI-BONE, Inc. ($SIBN) and Director in Xtant Medical Holdings, Inc. ($XTNT) and 10% Owner in Roka BioScience, Inc. ($ROKA) and Director in Roka BioScience, Inc. ($ROKA) and 10% Owner in Kala Pharmaceuticals, Inc. ($KALA) and Director in Otonomy, Inc. ($OTIC) and 10% Owner in Arsanis, Inc. ($ASNS) and 10% Owner in Principia Biopharma Inc. ($PRNB) and Director in Acutus Medical, Inc. ($AFIB) and Director in SYNLOGIC, INC. ($MIRN) and 10% Owner in NeuroPace Inc ($NPCE) and 10% Owner in GRAYBUG VISION, INC. ($GRAY) and 10% Owner in Sientra, Inc. ($SIEN) and 10% Owner in TELA Bio, Inc. ($TELA) and Director in Loxo Oncology, Inc. ($LOXO) and 10% Owner in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in Dimension Therapeutics, Inc. ($DMTX) and 10% Owner in Guardant Health, Inc. ($GH) and 10% Owner in ViewRay, Inc. ($VRAY) and Director in ViewRay, Inc. ($VRAY) and Director in Turning Point Therapeutics, Inc. ($TPTX) and in Tricida, Inc. ($TCDA) and Director in Tricida, Inc. ($TCDA) and 10% Owner in Inspire Medical Systems, Inc. ($INSP) and Director in Inspire Medical Systems, Inc. ($INSP) and Director in Synthorx, Inc. ($THOR) and 10% Owner in scPharmaceuticals Inc. ($SCPH) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in ALPINE IMMUNE SCIENCES, INC. ($NVLS) and Director in Corvus Pharmaceuticals, Inc. ($CRVS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and Director in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in Aeglea BioTherapeutics, Inc. ($AGLE) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and Director in Intellia Therapeutics, Inc. ($NTLA) and 10% Owner in Alector, Inc. ($ALEC) and Director in Alector, Inc. ($ALEC) and Director in Decibel Therapeutics, Inc. ($DBTX) and Director in NextCure, Inc. ($NXTC) and Director in LogicBio Therapeutics, Inc. ($LOGC) and Director in Silverback Therapeutics, Inc. ($SBTX) and Director in IMARA Inc. ($IMRA) and Director in Keros Therapeutics, Inc. ($KROS) and Director in Prelude Therapeutics Inc ($PRLD) and Director in PMV Pharmaceuticals, Inc. ($PMVP) and Director in ARMO BioSciences, Inc. ($ARMO) and Director in resTORbio, Inc. ($TORC) and Director in Prevail Therapeutics Inc. ($PRVL) and 10% Owner in SpringWorks Therapeutics, Inc. ($SWTX) and Director in Edgewise Therapeutics, Inc. ($EWTX) and Director in 89bio, Inc. ($ETNB) and Director in Arcutis Biotherapeutics, Inc. ($ARQT) and in Kinnate Biopharma Inc. ($KNTE) and Director in Oric Pharmaceuticals, Inc. ($ORIC) and Director in Repare Therapeutics Inc. ($RPTX) and Director in Fusion Pharmaceuticals Inc. ($FUSN) and Director in Terns Pharmaceuticals, Inc. ($TERN) and Director in Ikena Oncology, Inc. ($IKNA).
ORBIMED ADVISORS LLC in Oric Pharmaceuticals, Inc.
Trading Symbol: ORICIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of ORBIMED ADVISORS LLC: Director
Holdings: 2,240,440 shares
Latest Transaction: Mar 31 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of ORBIMED ADVISORS LLC in Oric Pharmaceuticals, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, XLRN, AFIB, ADAP, TORC, AGLE, ARPO, ALEC, ALPN, ARQT, ARMO, BOLD, AVDR, CNST, CRVS, CTIC, DBTX, DMTX, EWTX, FUSN, GKOS, GRAY, GH, IKNA, IMRA, INSP, NTLA, ICPT, KALA, KROS, KNTE, LOGC, LOXO, NPCE, NXTC, ORIC, OTIC, PIRS, PMVP, PRLD, PRVL, PRNB, RLYP, RPTX, RPBIF, RYTM, SCPH, SELB, SIBN, SIEN, SRRA, SBTX, ROKA, SWTX, STDY, SYBX, THOR, TELA, TERN, TCDA, TPTX, VRAY, ASNS, XTNT
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 31 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 23.93 | 27,869 | 666,905 | 2,212,571 | 2.2 M to 2.2 M (-1.24 %) |
Mar 31 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 23.31 | 75,555 | 1,761,187 | 2,240,440 | 2.3 M to 2.2 M (-3.26 %) |
Mar 26 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 23.88 | 27,816 | 664,246 | 2,315,995 | 2.3 M to 2.3 M (-1.19 %) |
Mar 26 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 23.88 | 27,816 | 664,246 | 2,315,995 | 2.3 M to 2.3 M (-1.19 %) |
Mar 26 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 24.70 | 51,523 | 1,272,618 | 2,343,811 | 2.4 M to 2.3 M (-2.15 %) |
Mar 26 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 24.70 | 51,523 | 1,272,618 | 2,343,811 | 2.4 M to 2.3 M (-2.15 %) |
Mar 26 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 24.80 | 32,959 | 817,383 | 2,395,334 | 2.4 M to 2.4 M (-1.36 %) |
Mar 26 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 24.80 | 32,959 | 817,383 | 2,395,334 | 2.4 M to 2.4 M (-1.36 %) |
Mar 23 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 24.32 | 3,992 | 97,085 | 2,428,293 | 2.4 M to 2.4 M (-0.16 %) |
Mar 23 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 26.47 | 7,673 | 203,104 | 2,432,285 | 2.4 M to 2.4 M (-0.31 %) |
Mar 23 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 26.47 | 21,275 | 563,149 | 2,439,958 | 2.5 M to 2.4 M (-0.86 %) |
Mar 18 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 28.03 | 6,059 | 169,834 | 2,461,233 | 2.5 M to 2.5 M (-0.25 %) |
Mar 18 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 28.43 | 18,790 | 534,200 | 2,467,292 | 2.5 M to 2.5 M (-0.76 %) |
Mar 18 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 27.72 | 41,353 | 1,146,305 | 2,486,082 | 2.5 M to 2.5 M (-1.64 %) |
Mar 15 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 29.14 | 89,210 | 2,599,579 | 2,527,435 | 2.6 M to 2.5 M (-3.41 %) |
Mar 15 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 30.29 | 90,521 | 2,741,881 | 2,616,645 | 2.7 M to 2.6 M (-3.34 %) |
Mar 15 2021 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Sell | S | 33.04 | 58,551 | 1,934,525 | 2,707,166 | 2.8 M to 2.7 M (-2.12 %) |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 236,111 | 0 | 0 | |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 373,356 | 0 | 0 | |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 1,875,000 | 0 | 0 | |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 236,111 | 0 | 2,765,717 | 2.5 M to 2.8 M (+9.33 %) |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 373,356 | 0 | 2,529,606 | 2.2 M to 2.5 M (+17.32 %) |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 1,875,000 | 0 | 2,156,250 | 281.3 K to 2.2 M (+666.67 %) |
Apr 28 2020 | ORIC | Oric Pharmaceutica ... | ORBIMED ADVISORS LLC | Director | Buy | P | 16.00 | 281,250 | 4,500,000 | 281,250 | 0 to 281.3 K |
Page: 1